https://mindmedicinelaw.com/briefing/cross-national-psychedelic-use-study-icps-findings-20260605-10743The Psychedelic Journalen2026-06-07T15:03:15.224139+00:00Cross-National Psychedelic Use Study: ICPS Findingspsychedelic use, ICPS study, psilocybin, LSD, MDMA, ketamine, clinical trials, therapeutic guidelines, adverse health effects, nonmedical usehttps://mindmedicinelaw.com/briefing/ketamine-and-esketamine-for-resistant-depression-a-systematic-review-20260605-10754The Psychedelic Journalen2026-06-07T15:03:07.270035+00:00Ketamine and Esketamine for Resistant Depression: A Systematic Reviewketamine, esketamine, treatment-resistant depression, rapid antidepressant effects, clinical trials, mental health policy, NMDA receptor antagonists, long-term safety, healthcare utilizationhttps://mindmedicinelaw.com/briefing/clearmind-medicine-s-cmnd-100-trial-insights-webinar-20260605-10196The Psychedelic Journalen2026-06-06T22:03:58.284018+00:00Clearmind Medicine's CMND-100 Trial Insights Webinarclearmind medicine, cmnd-100 trial, psychedelic research, clinical trials, meai compound, market strategies, therapeutic potential, regulatory hurdleshttps://mindmedicinelaw.com/briefing/epa-s-tsca-chemical-submissions-implications-for-psychedelics-20260605-10065The Psychedelic Journalen2026-06-06T22:03:52.251890+00:00EPA's TSCA Chemical Submissions: Implications for PsychedelicsEPA, TSCA, chemical regulation, psychedelic research, Premanufacture Notice, Significant New Use Notice, regulatory compliance, new chemical substances, market impact, safety assessmenthttps://mindmedicinelaw.com/briefing/observing-awe-in-psilocybin-therapy-new-methods-explored-20260605-10434The Psychedelic Journalen2026-06-06T15:05:13.270510+00:00Observing Awe in Psilocybin Therapy: New Methods Exploredpsilocybin-assisted therapy, awe narration, coding system, psychedelic therapy, therapeutic mechanisms, clinical trials, advanced cancer, psychedelic research, therapeutic outcomes, scalable systemshttps://mindmedicinelaw.com/briefing/arizona-s-psilocybin-trial-progress-and-implications-20260605-10354The Psychedelic Journalen2026-06-05T22:04:21.914941+00:00Arizona's Psilocybin Trial: Progress and Implicationspsilocybin trial, Arizona, psychedelic research, mental health, clinical trials, regulatory policy, serotonin receptors, Schedule I substance, treatment-resistant conditionshttps://mindmedicinelaw.com/briefing/epa-s-proposed-snurs-under-tsca-impacts-on-psychedelic-research-20260605-10064The Psychedelic Journalen2026-06-05T22:04:14.238920+00:00EPA's Proposed SNURs Under TSCA: Impacts on Psychedelic ResearchEPA, SNURs, TSCA, psychedelic research, chemical substances, regulatory compliance, manufacturing, import, notification, policyhttps://mindmedicinelaw.com/briefing/case-reports-in-psychedelic-research-impact-and-implications-20260604-10128The Psychedelic Journalen2026-06-06T22:04:26.095008+00:00Case Reports in Psychedelic Research: Impact and Implicationscase reports, psychedelic research, evidence hierarchy, esketamine approval, FDA, adverse event reporting, clinical trials, medical literature, treatment advancements, anecdotal evidencehttps://mindmedicinelaw.com/briefing/case-reports-their-role-in-treatment-approvals-and-medicine-20260604-10132The Psychedelic Journalen2026-06-06T22:04:16.869654+00:00Case Reports: Their Role in Treatment Approvals and Medicinecase reports, FDA approvals, esketamine, treatment-resistant depression, medical advancements, evidence hierarchy, rare drug reactions, post-marketing surveillance, clinical trials, medical researchhttps://mindmedicinelaw.com/briefing/ketamine-assisted-couple-therapy-new-frontiers-explored-20260604-10084The Psychedelic Journalen2026-06-06T22:04:10.284829+00:00Ketamine-Assisted Couple Therapy: New Frontiers Exploredketamine-assisted psychotherapy, couple therapy, emotional expression, trust enhancement, psychedelic therapy, mental healthcare, therapeutic protocols, psychotherapy modalities, relational dysfunction, attachment processeshttps://mindmedicinelaw.com/briefing/challenges-in-euthanasia-for-mental-disorders-legal-and-ethical-complexities-20260604-10131The Psychedelic Journalen2026-06-06T22:04:04.117858+00:00Challenges in Euthanasia for Mental Disorders: Legal and Ethical Complexitieseuthanasia, assisted suicide, mental disorders, legal frameworks, bioethics, psychiatric evaluation, multidisciplinary approach, safeguard systems, decision-making capacity, international variabilityhttps://mindmedicinelaw.com/briefing/kainic-acid-pig-model-advances-epilepsy-neuromodulation-20260604-10445The Psychedelic Journalen2026-06-06T15:04:47.101134+00:00Kainic Acid Pig Model Advances Epilepsy Neuromodulationkainic acid, porcine model, mesial temporal lobe epilepsy, neuromodulation, implantable devices, translational research, epilepsy therapies, clinical trials, neuroscience, large-animal modelshttps://mindmedicinelaw.com/briefing/psychedelics-for-chronic-pain-review-highlights-challenges-20260604-10400The Psychedelic Journalen2026-06-06T15:04:38.305695+00:00Psychedelics for Chronic Pain: Review Highlights Challengespsychedelics, chronic pain, clinical trials, neuroplasticity, safety considerations, regulatory challenges, psilocybin, LSD, pain management, future researchhttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-for-social-anxiety-trial-insights-20260604-10421The Psychedelic Journalen2026-06-06T15:04:29.523178+00:00MDMA-Assisted Therapy for Social Anxiety: Trial InsightsMDMA, MDMA-Assisted Therapy, social anxiety disorder, clinical trial, psychedelics, mental health treatment, therapy, neuroscience, psychiatry, regulatory implicationshttps://mindmedicinelaw.com/briefing/eeg-study-explores-awe-in-affective-disorders-20260604-10118The Psychedelic Journalen2026-06-05T22:04:40.390349+00:00EEG Study Explores Awe in Affective Disordersaffective disorders, awe experience, EEG study, virtual reality, emotional processing, neural activity, theta oscillations, therapeutic interventions, mental health treatment, neurobiological researchhttps://mindmedicinelaw.com/briefing/ketamine-induced-neuronal-death-adult-rats-study-insights-20260604-10129The Psychedelic Journalen2026-06-05T22:04:33.097835+00:00Ketamine-Induced Neuronal Death: Adult Rats Study Insightsketamine neurotoxicity, adult female rats, neuronal necrosis, norketamine metabolite, depression treatment, safety profile, clinical research, age-specific risks, sex-specific vulnerability, psychedelic researchhttps://mindmedicinelaw.com/briefing/cannabis-cue-task-shows-no-neural-differences-across-cud-risk-groups-20260603-10086The Psychedelic Journalen2026-06-07T15:03:41.193426+00:00Cannabis Cue Task Shows No Neural Differences Across CUD-Risk Groupscannabis use disorder, neural differences, inhibitory control, prefrontal activation, CUDIT-R, functional near-infrared spectroscopy, behavioral tasks, diagnostic tools, clinical practice, neural adaptationshttps://mindmedicinelaw.com/briefing/ketogenic-therapy-in-anorexia-nervosa-promising-trial-results-20260603-10087The Psychedelic Journalen2026-06-07T15:03:32.875594+00:00Ketogenic Therapy in Anorexia Nervosa: Promising Trial Resultsketogenic therapy, anorexia nervosa, psychiatric disorder, eating disorder treatment, clinical trial, dietary intervention, symptom management, public health, neuroscience, feasibility studyhttps://mindmedicinelaw.com/briefing/bnst-activity-in-alcohol-abstinence-implications-for-aud-treatment-20260603-10136The Psychedelic Journalen2026-06-07T15:03:23.781723+00:00BNST Activity in Alcohol Abstinence: Implications for AUD TreatmentBNST activity, alcohol use disorder, AUD treatment, neurobiology, abstinence, aversion-resistant intake, dBNST, phenotype-specific adaptations, operant task, calcium transientshttps://mindmedicinelaw.com/briefing/ibogaine-s-role-in-addiction-treatment-a-literature-review-20260603-10119The Psychedelic Journalen2026-06-06T15:04:56.117360+00:00Ibogaine's Role in Addiction Treatment: A Literature Reviewibogaine, addiction treatment, substance use disorders, clinical trials, cardiac risks, regulatory criteriahttps://mindmedicinelaw.com/briefing/n100-and-fronto-limbic-metabolism-in-mdd-new-insights-20260603-10135The Psychedelic Journalen2026-06-05T22:04:47.386129+00:00N100 and Fronto-Limbic Metabolism in MDD: New InsightsN100 potential, major depressive disorder, GABAergic systems, cerebral glucose metabolism, transcranial magnetic stimulation, compensatory mechanism, fronto-limbic metabolism, Hamilton Depression Rating Scale, targeted therapies, neurophysiological mechanismhttps://mindmedicinelaw.com/briefing/gut-brain-axis-in-anxiety-and-depression-new-insights-20260602-10733The Psychedelic Journalen2026-06-07T15:03:51.475735+00:00Gut-Brain Axis in Anxiety and Depression: New Insightsgut-brain axis, anxiety disorders, depression, probiotics, dietary interventions, mental health, dysbiosis, neuroscience, clinical trials, public healthhttps://mindmedicinelaw.com/briefing/brazil-s-psychedelic-psychiatric-use-a-scoping-review-20260530-10442The Psychedelic Journalen2026-06-06T15:05:05.529026+00:00Brazil's Psychedelic Psychiatric Use: A Scoping Reviewbrazil, ayahuasca, psychedelic research, psychiatric disorders, dmt, ibogaine, substance use disorders, clinical trials, mental health, cultural integrationhttps://mindmedicinelaw.com/briefing/ketamine-s-dual-effects-neurotoxicity-and-neuroprotection-20260527-10175The Psychedelic Journalen2026-06-05T22:04:04.870135+00:00Ketamine's Dual Effects: Neurotoxicity and Neuroprotectionketamine, esketamine, neurotoxicity, neuroprotection, clinical guidelines, brain health, therapeutic use, systematic review, neuroscience, public health